Telix Pharmaceuticals Limited
TLX
$17.53
$0.231.33%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 136.60M | 140.46M | 124.52M | 115.09M | 91.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 136.60M | 140.46M | 124.52M | 115.09M | 91.80M |
| Cost of Revenue | 52.46M | 53.94M | 51.82M | 39.22M | 36.47M |
| Gross Profit | 84.14M | 86.52M | 72.71M | 75.87M | 55.32M |
| SG&A Expenses | 36.43M | 37.46M | 32.52M | 30.22M | 22.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 174.00K | 178.90K | -1.81M | 1.64M | -240.20K |
| Total Operating Expenses | 125.05M | 128.58M | 112.70M | 96.34M | 84.99M |
| Operating Income | 11.55M | 11.87M | 11.82M | 18.75M | 6.81M |
| Income Before Tax | 6.96M | 7.16M | 6.03M | 16.80M | 5.01M |
| Income Tax Expenses | 361.30K | 371.50K | -1.67M | 4.98M | -1.35M |
| Earnings from Continuing Operations | 6.60M | 6.79M | 7.70M | 11.82M | 6.36M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.60M | 6.79M | 7.70M | 11.82M | 6.36M |
| EBIT | 11.55M | 11.87M | 11.82M | 18.75M | 6.81M |
| EBITDA | 12.20M | 12.54M | 13.42M | 19.59M | 7.49M |
| EPS Basic | 0.02 | 0.02 | 0.02 | 0.04 | 0.02 |
| Normalized Basic EPS | 0.02 | 0.02 | 0.02 | 0.03 | 0.01 |
| EPS Diluted | 0.02 | 0.02 | 0.02 | 0.04 | 0.02 |
| Normalized Diluted EPS | 0.02 | 0.02 | 0.02 | 0.03 | 0.01 |
| Average Basic Shares Outstanding | 334.73M | 334.73M | 331.60M | 323.86M | 320.85M |
| Average Diluted Shares Outstanding | 351.47M | 351.47M | 346.18M | 331.62M | 329.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
